Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Declines By 19.6%

Atyr PHARMA INC (NASDAQ:ATYR) saw a large decline in short interest in July. As of July 31st, there was short interest totalling 270,600 shares, a decline of 19.6% from the July 15th total of 336,600 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 451,500 shares, the short-interest ratio is currently 0.6 days.

Atyr PHARMA Trading Down 4.5 %

Shares of NASDAQ:ATYR traded down $0.09 during midday trading on Friday, hitting $1.91. 796,039 shares of the stock were exchanged, compared to its average volume of 482,658. The company has a market capitalization of $131.81 million, a PE ratio of -2.12 and a beta of 1.25. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, equities research analysts expect that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Paul Schimmel purchased 41,052 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was acquired at an average price of $1.74 per share, for a total transaction of $71,430.48. Following the acquisition, the director now directly owns 354,075 shares of the company’s stock, valued at approximately $616,090.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ATYR shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Atyr PHARMA in a research note on Wednesday.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.